Phase Ib (megestrol acetate, ipatasertib) for Endometrial Endometrioid Adenocarcinoma
This trial tests if a combination of drugs can help treat endometrial cancer more effectively than one drug alone.
- Recurrent Endometrial Endometrioid Adenocarcinoma
- FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
- Stage IV Uterine Cancer
- Metastatic Endometrial Endometrioid Adenocarcinoma
- Endometrial Endometrioid Adenocarcinoma
4 Primary · 3 Secondary · Reporting Duration: Up to 5 years
3 Treatment Groups
Phase II (megestrol acetate)
1 of 3
Phase Ib (megestrol acetate, ipatasertib)
1 of 3
Phase II (megestrol acetate, ipatasertib)
1 of 3
96 Total Participants · 3 Treatment Groups
Primary Treatment: Phase Ib (megestrol acetate, ipatasertib) · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · Female Participants · 22 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the enrolment size of this study?
"Affirmative. According to clinicaltrials.gov, this clinical trial is still recruiting participants after first being advertised on January 13th 2023 and most recently edited on the 28th of that same month. This investigation requires 96 recruits from a single location." - Anonymous Online Contributor
Is there availability for prospective participants to join this investigation?
"Yes, according to clinicaltrials.gov this medical trial is actively enrolling participants at one location. It was first posted on 13th of January 2023 and the most recent update occurred 28 days later. 96 individuals need to be recruited for full completion of the study." - Anonymous Online Contributor